Literature DB >> 35233528

Adverse clinical outcomes associated with infections by Enterobacterales producing ESBL (ESBL-E): a systematic review and meta-analysis.

Weiping Ling1, Luis Furuya-Kanamori1, Yukiko Ezure1, Patrick N A Harris1,2, David L Paterson1,3.   

Abstract

OBJECTIVES: Enterobacterales producing ESBL (ESBL-E) have been notable for their rapid expansion in community settings. This systematic review and meta-analysis aimed to summarize evidence investigating the association between ESBL-E infection and adverse clinical outcomes, defined as bacteraemia, sepsis or septic shock, and all-cause mortality in adult patients.
METHODS: Database search was conducted in PubMed, Scopus and EMBASE. In general, studies were screened for effect estimates of ESBL-E colonization or infection on clinical outcomes with non-ESBL-producing Enterobacterales as comparator, adult populations and molecular ascertainment of ESBL gene. Meta-analysis was performed using the inverse variance heterogeneity model.
RESULTS: Eighteen studies were identified, including 1399 ESBL-E and 3200 non-ESBL-E infected patients. Sixteen of these studies included only bacteraemic patients. Mortality was studied in 17 studies and ESBL-E infection was significantly associated with higher odds of mortality compared with non-ESBL-producing Enterobacterales infection (OR = 1.70, 95% CI: 1.15-2.49, I 2=58.3%). However, statistical significance did not persist when adjusted estimates were pooled (aOR = 1.67, 95% CI: 0.52-5.39, I 2=78.1%). Septic shock was studied in seven studies and all included only bacteraemic patients. No association between ESBL-E infection and shock was found (OR = 1.23, 95% CI: 0.75-2.02, I 2=14.8%). Only one study investigated the association between ESBL-E infection and bacteraemia.
CONCLUSIONS: Infections by ESBL-E appear to be significantly associated with mortality but not septic shock. Available studies investigating bacteraemia and shock as an intermediate outcome of ESBL-E infections are lacking. Future studies investigating the relationship between clinical outcomes and molecular characteristics of resistant strains are further warranted, along with studies investigating this in non-bacteraemic patients.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2021        PMID: 35233528      PMCID: PMC8210200          DOI: 10.1093/jacamr/dlab068

Source DB:  PubMed          Journal:  JAC Antimicrob Resist        ISSN: 2632-1823


  53 in total

1.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

2.  Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.

Authors:  Young Eun Ha; Cheol-In Kang; Min Kyeong Cha; So Yeon Park; Yu Mi Wi; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  Int J Antimicrob Agents       Date:  2013-09-07       Impact factor: 5.283

Review 3.  The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community.

Authors:  Yihienew M Bezabih; Wilber Sabiiti; Endalkachew Alamneh; Alamneh Bezabih; Gregory M Peterson; Woldesellassie M Bezabhe; Anna Roujeinikova
Journal:  J Antimicrob Chemother       Date:  2021-01-01       Impact factor: 5.790

Review 4.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

5.  Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.

Authors:  Nan-Yao Lee; Ching-Chi Lee; Chia-Wen Li; Ming-Chi Li; Po-Lin Chen; Chia-Ming Chang; Wen-Chien Ko
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

6.  Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Drosos E Karageorgopoulos; Konstantinos Z Vardakas
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

7.  The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.

Authors:  Jin Young Ahn; Hea Won Ann; Yongduk Jeon; Mi Young Ahn; Dong Hyun Oh; Yong Chan Kim; Eun Jin Kim; Je Eun Song; In Young Jung; Moo Hyun Kim; Wooyoung Jeong; Nam Su Ku; Su Jin Jeong; Jun Yong Choi; Dongeun Yong; Young Goo Song; June Myung Kim
Journal:  BMC Infect Dis       Date:  2017-05-03       Impact factor: 3.090

8.  Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan.

Authors:  Yuko Komatsu; Kei Kasahara; Takashi Inoue; Sang-Tae Lee; Tetsuro Muratani; Hisakazu Yano; Tadaaki Kirita; Keiichi Mikasa
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

9.  Clinical outcome of Escherichia coli bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study.

Authors:  Qing Zhang; Hao-Yang Gao; Ding Li; Zheng Li; Shan-Shan Qi; Shan Zheng; Chang-Sen Bai; Si-He Zhang
Journal:  Infect Drug Resist       Date:  2019-02-11       Impact factor: 4.003

Review 10.  Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis.

Authors:  Amber Martin; Kyle Fahrbach; Qi Zhao; Thomas Lodise
Journal:  Open Forum Infect Dis       Date:  2018-06-28       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.